• Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright

    Source: Buzz FX / 22 Jan 2025 02:50:17   America/New_York


    Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright Written by MarketBeat January 22, 2025 Share Link copied to clipboard. HC Wainwright reissued their buy rating on shares of Summit Therapeutics ( NASDAQ:SMMT - Free Rep
    Read more...
Share on,